SB-706375

nonpeptidic urotensin-II receptor antagonist; structure in first source

Also Known As:

(2-bromo-4,5-dimethoxy-N-(3-(R)-1-methyl-pyrrolidin-3-yloxy)-4-trifluro-methyl-phenyl)-benzenesulfonamide HCl; (2-bromo-4,5-dimethoxy-N-(3-(R)-1-methyl-pyrrolidin-3-yloxy)-4-trifluro-methyl-phenyl)-benzenesulphonamide HCl

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Chen, Shuo: 1 article (12/2019)
2.	Chen, Zhi-Wu: 1 article (12/2019)
3.	Du, Juan: 1 article (12/2019)
4.	Duan, Jing-Si: 1 article (12/2019)
5.	Sun, Xiao-Qing: 1 article (12/2019)
6.	Ashton, Nick: 1 article (06/2012)
7.	Forty, Ellen J: 1 article (06/2012)

Related Diseases

1.	Reperfusion Injury 12/01/2019 - "Urotensin-#receptor antagonist SB-706375 protected isolated rat heart from ischaemia-reperfusion injury by attenuating myocardial necrosis via RhoA/ROCK/RIP3 signalling pathway."
2.	Necrosis 12/01/2019 - "Urotensin-#receptor antagonist SB-706375 protected isolated rat heart from ischaemia-reperfusion injury by attenuating myocardial necrosis via RhoA/ROCK/RIP3 signalling pathway."
3.	Body Weight (Weight, Body) 06/01/2012 - "Infusion of rat UII [6-60 pmol min(-1) (100 g body weight)(-1)] or rat urotensin-related peptide [6 pmol min(-1) (100 g body weight)(-1)] in anaesthetized 4-week-old SD rats had no influence on measured renal parameters; however, infusion of UT antagonist, SB-706375 (0.01 mg kg(-1) min(-1)), provoked a pronounced diuresis [vehicle 23.5 ± 1.9 versus antagonist 75.3 ± 12.5 μl min(-1) (100 g body weight)(-1); P < 0.001] and natriuresis, accompanied by modest increases in effective renal blood flow and glomerular filtration rate [vehicle 0.4 ± 0.1 versus antagonist 1.1 ± 0.2 ml min(-1) (100 g body weight)(-1); P < 0.0001] and a significant increase in fractional sodium excretion. "

Related Drugs and Biologics

1.	Urotensins
2.	Sodium
3.	Peptides (Polypeptides)